-
05-212023
Forlong Biotech Announces FDA Clearance for Phase I Clinical Trial of FL115, a Best-in-Class IL-15 Super-Agonist, as IV Monotherapy in Advanced Solid Tumors
-
02-062023
Forlong Biotech Announces $15 Million in Series A Financing to Advance Best-in-Class IL-15 Super Agonist FL115 Into Clinical Trials
苏公网安备32050502011888号